Clinical activity and safety of naptumomab estafenatox (NAP) and docetaxel in patients (pts) with checkpoint inhibitor (CPI) -pretreated advanced/metastatic non-small cell lung cancer (NSCLC): Preliminary results of a P2 trial

被引：0
|
作者：
Larson, Timothy
Jotte, Robert M.
Abdelaziz, Ahmed Mohammed Fouad
Konduri, Kartik
Richards, Donald A.
Meshad, Michael W.
Nagaiah, Govardhanan
Spira, Alexander I.
Khandelwal, Pankaj
Lorber, Ilana
Kedem, Tal Hetzroni
Rozencweig, Marcel
Fields, Scott Z.
机构：
[1] Minnesota Oncol Hematol PA, Minneapolis, MN USA
[2] Rocky Mt Canc Ctr, Lone Tree, CO USA
[3] Arizona Oncol, Tucson, AZ USA
[4] Texas Oncol PA, Dallas, TX USA
[5] Texas Oncol Tyler, Tyler, TX USA
[6] Southern Canc Ctr, Daphne, AL USA
[7] Arizona Oncol, Goodyear, AZ USA
[8] Virginia Canc Specialists, Fairfax, VA USA
[9] Texas Oncol Odessa, Odessa, TX USA
[10] NeoTx Ltd, Rehovot, Israel
[11] NeoTX Therapeut, Rehovot, Israel
[12] NeoTX, Princeton, NJ USA
[13] NeoTX Therapeut, Boka Raton, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8615
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel in pretreated patients (pts) with metastatic non-small cell lung cancer (NSCLC)
    Riely, G. J.
    Gettinger, S. N.
    Stoller, R. G.
    Gabrail, N. Y.
    Dy, G. K.
    Weiss, G. J.
    Tunkey, C.
    Skliris, G.
    Strychor, S.
    Dunbar, J.
    DeLucia, D.
    Ross, R. W.
    Gray, J. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Safety and preliminary activity of naptumomab estafenatox (NAP) and durvalumab in patients with advanced or metastatic solid tumors: interim results from a phase 1b trial
    Geva, Ravit
    Stemmer, Salomon
    Perets, Ruth
    Maurice-Dror, Corinne
    Ben-Ami, Eitan
    Raphael, Ari
    Kumar, Sanjeev
    Lorber, Ilana
    Kedem, Tal Hetzroni
    Fields, Scott Z.
    Rozencweig, Marcel
    Golan, Talia
    CANCER RESEARCH, 2023, 83 (08)
  • [3] Comorbidity in clinical trial patients with advanced or metastatic non-small cell lung cancer (NSCLC).
    Kosov, Maxim
    Kumar, Akhil
    Belotserkovskiy, Maxim
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Preliminary results of a phase II trial of Docetaxel (D) and Gemcitabine (G) in advanced Non-Small Cell Lung Cancer (NSCLC) in elderly and/or unfit patients (PTS)
    Buffoni, Lucio
    Grillo, Raffaella
    Barone, Carla
    Dongiovanni, Diego
    Gaspari, Fabio
    Giacobino, Alice
    Consito, Lorena
    Ciuffreda, Libero
    Schena, Marina
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S668 - S668
  • [5] Cobolimab With Dostarlimab and Docetaxel in Patients (pts) With Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung
    Kim, Hye Ryun
    Gridelli, Cesare
    Kapur, Dinesh
    Tufman, Amanda
    Felip, Enriqueta
    Velcheti, Vamsidhar
    Kim, Yu Jung
    Goetze, Thorsten
    Lopez, Pilar Garrido
    Corre, Romain
    Penkov, Konstantin
    Anjum, Rana
    Di Pace, Brian
    Liu, Wenlei
    Borgovan, Theo
    Ledger, Danielle
    Carver, Jennifer
    Waszak, Angela
    Dhar, Arindam
    Novello, Silvia
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 163 - 163
  • [6] Phase (ph) 2 study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC):: Preliminary results.
    Fanucchi, MP
    Belt, RJ
    Fossella, FV
    Natale, RB
    Robert, F
    Fidias, P
    Kelly, K
    Kashala, O
    Shenkein, DP
    Schiller, JH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 643S - 643S
  • [7] Interim results of a phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC)
    Zalcberg, JR
    Bishop, JF
    Millward, MJ
    Zimet, A
    Laird, J
    Barter, C
    Seward, D
    McKeage, MJ
    Friedlander, ML
    Toner, G
    Berille, J
    Blanc, C
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1084 - 1084
  • [8] Chronic immune checkpoint inhibitor (ICI) pneumonitis in patients (pts) with non-small cell lung cancer (NSCLC).
    Stuart, Jessica
    Ricciuti, Biagio
    Alessi, Joao Victor Machado
    Nishino, Mizuki
    Awad, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC)
    Subramanian, J.
    Moreno, V.
    Bosch-Barrera, J.
    Pikiel, J.
    Kristeleit, R.
    Guo, W.
    Danaee, H.
    Im, E.
    Roda, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S886 - S887
  • [10] Weekly docetaxel (TXT) and cisplatin (CIS) for chemonaive patients (Pts) with advanced non-small cell lung cancer (NSCLC)
    Aisner, J
    Geunsch, L
    Schwarz, S
    Zheng, L
    Wojtaszek, C
    Lutzker, S
    LUNG CANCER, 2005, 49 : S233 - S233
12345